Physician profile
Asif Khan
NPI 1396825246
$5,286.12
in general payments reported to CMS, 2019-2025
22 companies · $854 in 2025
The $854 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $165 · 2021: $914 · 2022: $1,078 · 2023: $1,192 · 2024: $858 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,903.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,179.36 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Csl Behring | $704.14 | 2019-2025 | Andembry, Haegarda, Kcentra |
| Genzyme Corporation | $640.87 | 2021-2025 | |
| Biocryst US Sales Co., LLC | $345.23 | 2022-2025 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $177.94 | 2019-2025 | |
| Amgen INC. | $170.28 | 2022-2023 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $165.01 | 2021-2022 | |
| Genentech USA, INC. | $158.17 | 2019-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $146.74 | 2025 | Neffy |
| Pfizer INC. | $117.19 | 2019-2023 | |
| Glaxosmithkline, LLC. | $80.10 | 2021-2024 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $62.11 | 2022-2024 | Takhzyro |
| Teva Pharmaceuticals USA, INC. | $59.48 | 2022 | |
| Cycle Pharmaceuticals INC | $57.73 | 2025 | Sajazir |
| Merck Sharp & Dohme LLC | $55.66 | 2021-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $54.89 | 2023 | Ayvakit |
| Paratek Pharmaceuticals, INC. | $23.92 | 2025 | Xhance |
| Hikma Pharmaceuticals USA | $20.38 | 2023 | Ryaltris |
| Aimmune Therapeutics, INC. | $19.55 | 2022 | |
| Kaleo, INC. | $17.79 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.25 | 2022 | |
| Optinose US, INC. | $13.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asif Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.